1.25

4.17% 0.05

After Hours: 1.24 -0.01 -0.80%

Lineage Cell Therapeutics Inc (LCTX)

Overview News Price History Option Chain Discussions Forecast Stock Split

Lineage Cell Therapeutics Inc stock is traded at $1.25, with a volume of 1.39M. It is up +4.17% in the last 24 hours and up +0.00% over the past month. Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Previous Close:

$1.20

Open:

$1.22

24h Volume:

1.39M

Relative Volume:

1.17

Market Cap:

$311.62M

Revenue:

$14.78M

Net Income/Loss:

$-64.01M

P/E Ratio:

-4.3509

EPS:

-0.2873

Net Cash Flow:

$-22.59M

1W Performance:

+1.63%

1M Performance:

+0.00%

6M Performance:

-29.38%

1Y Performance:

+45.62%

1-Day Range:

$1.22

$1.27

1-Week Range:

$1.20

$1.3179

52-Week Range:

$0.829

$2.09

Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile

Name

Lineage Cell Therapeutics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

510-871-4188

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA

Employee

Twitter

@LineageCell

Next Earnings Date

2026-05-12

Latest SEC Filings

LCTX's Discussions on Twitter

Compare LCTX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LCTX Lineage Cell Therapeutics Inc	1.25	306.64M	14.78M	-64.01M	-22.59M	-0.2873
VRTX Vertex Pharmaceuticals Inc	458.99	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	607.93	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	892.26	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	282.72	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	157.77	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-20-24	Initiated	Craig Hallum	Buy
Nov-02-22	Initiated	Robert W. Baird	Outperform
Jun-14-22	Initiated	B. Riley Securities	Buy
Aug-19-21	Initiated	Noble Capital Markets	Outperform
Mar-31-21	Initiated	Cantor Fitzgerald	Overweight

Lineage Cell Therapeutics Inc Stock (LCTX) Latest News

Jun 15, 2026

Lineage Cell Therapeutics joins panel on novel treatments at Clinical Trials at the Summit - Traders Union

Jun 15, 2026

Jun 12, 2026

Lineage Cell Shareholders Reaffirm Governance and Executive Pay - TipRanks

Jun 12, 2026

Lineage Cell (NYSE: LCTX) investors back board, say-on-pay as OPC1 grant bid withdrawn - Stock Titan

Jun 12, 2026

Jun 07, 2026

LCTX Q1 2026 Earnings: EPS Miss Reflects Ongoing R&D InvestmentTrough Earnings Signal - newsline.com

Jun 07, 2026

Jun 06, 2026

LCTX Q1 2026 Earnings: EPS Misses Estimates by 47% as Company Continues Clinical DevelopmentReturn On Assets - newsline.com

Jun 06, 2026

Jun 04, 2026

How The Lineage Cell Therapeutics (LCTX) Story Is Shifting With New Data And Analyst Targets - Yahoo Finance

Jun 04, 2026

Jun 02, 2026

LCTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Jun 02, 2026

May 29, 2026

Lineage Cell Therapeutics (LCTX) price target increased by 14.58% to 5.61 - MSN

May 29, 2026

LCTX Q1 2026 Earnings: Wider Loss Than Expected Amid Ongoing Pipeline DevelopmentForward EPS Estimate - newsline.com

May 29, 2026

LCTX Q1 2026 Earnings: Missed Estimates as R&D Spending Weighs on Bottom LineHealthcare Earnings Report - The Legal Advocate

May 29, 2026

May 28, 2026

Lineage Cell Therapeutics (LCTX) Gains 3% as Biotech Sector Finds SupportNHNL Ratio - The Legal Advocate

May 28, 2026